<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2017-493-499</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2430</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Структура кардиоваскулярной коморбидности у больных с тяжелыми формами псориаза: данные ретроспективного анализа госпитальной когорты</article-title><trans-title-group xml:lang="en"><trans-title>THE PATTERN OF CARDIOVASCULAR COMORBIDITY IN PATIENTS WITH SEVERE FORMS OF PSORIASIS: DATA OF RETROSPECTIVE ANALYSIS OF A HOSPITAL COHORT</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баткаева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Batkaeva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198 Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>6, Miklukho-Maklai St., Moscow 117198</p></bio><email xlink:type="simple">nbatkaeva.derm@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коротаева</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Korotaeva</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баткаев</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Batkaev</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198 Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>6, Miklukho-Maklai St., Moscow 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Peoples' Friendship University of Russia (RUDN University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>27</day><month>10</month><year>2017</year></pub-date><volume>55</volume><issue>5</issue><fpage>493</fpage><lpage>499</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Баткаева Н.В., Коротаева Т.В., Баткаев Э.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Баткаева Н.В., Коротаева Т.В., Баткаев Э.А.</copyright-holder><copyright-holder xml:lang="en">Batkaeva N.V., Korotaeva T.V., Batkaev E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2430">https://rsp.mediar-press.net/rsp/article/view/2430</self-uri><abstract><p>Псориаз (Пс) и псориатический артрит (ПсА), кроме поражения кожи и костно-суставного аппарата, сопровождаются разнообразными коморбидными заболеваниями, в первую очередь сердечно-сосудистой системы (ССС), что способствует уменьшению продолжительности жизни больных в среднем на 5–7 лет. Данных о распространенности и структуре заболеваний ССС в российской когорте больных с тяжелыми формами Пс и ПсА немного. Получение такой информации может способствовать разработке программ скрининга и профилактики заболеваний ССС в данной группе пациентов.</p><p>Цель исследования – изучить распространенность и структуру заболеваний ССС в госпитальной когорте пациентов с тяжелыми формами Пс и ПсА.</p><sec><title>Материал и методы</title><p>Материал и методы. Проведен ретроспективный анализ медицинской документации 890 больных с тяжелыми формами Пс (516 мужчин и 347 женщин, средний возраст – 51,9±11,6 года, средняя длительность Пс – 11,6±0,6 года), находившихся на стационарном лечении в ГБУЗ МНПЦДК, филиал «Клиника им. В.Г. Короленко» ДЗМ в период 2010–2015 гг. Индекс тяжести Пс PASI составил в среднем 49,4±0,5. Частоту ПсА оценивали по коду L40.5, частоту заболеваний ССС определяли по зарегистрированным диагнозам в соответствии с кодами Международной классификации болезней 10-го пересмотра (МКБ-10): артериальная гипертензия (АГ; код МКБ-10 – I10–I15), ишемическая болезнь сердца (ИБС; I20–I25), атеросклероз (I70) и цереброваскулярные нарушения (ЦВН; I65–I66).</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. У 303 (34%) пациентов был выявлен ПсА. Общее число пациентов с патологией ССС составило 516 человек (59%). У больных ПсА АГ, ИБС и  атеросклероз, а также ЦВН регистрировались чаще, чем при Пс без артрита.</p></sec><sec><title>Выводы</title><p>Выводы. Заболевания ССС регистрируются более чем у половины больных госпитальной когорты с тяжелыми формами Пс. При ПсА заболевания ССС регистрируются чаще, чем при Пс без артрита. Среди заболеваний ССС в обеих группах лидирует по частоте АГ, более чем у половины больных выявлены ИБС и атеросклероз, реже встречались ЦВН.</p></sec></abstract><trans-abstract xml:lang="en"><p>Psoriasis (Ps) and psoriatic arthritis (PsA) are, in addition to skin and osteoarticular lesions, accompanied by a variety of comorbidities, primarily cardiovascular diseases (CVDs), which contributes to shorter life expectancy by on an average of 5–7 years. There are scarce data on the prevalence and pattern of CVDs in a Russian cohort of patients with severe forms of Ps and PsA. Obtaining such information can contribute to the elaboration of programs for screening and prevention of CVDs in this patient group.</p><sec><title>Objective</title><p>Objective: to study the prevalence and pattern of CVDs in a hospital cohort of patients with severe forms of Ps and PsA.</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. Medical records were retrospectively analyzed in 890 patients with severe forms of Ps (mean age, 51.9±11.6 years; mean Ps duration, 11.6±0.6 years); who had been treated at the Branch of the V.G. Korolenko Clinic, Moscow Research and Practical Center of Dermatovenereology and Cosmetology, in 2010 to 2015. The Psoriasis Area and Severity Index (PASI) averaged 49.4±0.5. The frequency of PsA was assessed by the code L40.5; that of SVDs was determined by the registered diagnoses in accordance with the codes of the International Classification of Diseases, 10th edition (ICD-10): hypertension (ICD-10 code I10–I15), coronary heart disease (CHD) (I20–I25), atherosclerosis (I70), and cerebrovascular disorders (I65–I66).</p></sec><sec><title>Results and discussion</title><p>Results and discussion. PsA was identified in 303 (34%) patients. There were a total of 516 (59%) patients with CVDs. Hypertension, CHD, atherosclerosis, and cerebrovascular disorders were more frequently recorded in patients with PsA than in those with PsA without arthritis.</p></sec><sec><title>Conclusion</title><p>Conclusion. CVDs are recorded in more than half of the hospital cohort patients with severe forms of Ps. CVDs are more frequently recorded in PsA than in Ps without arthritis. Hypertension among the SVDs is a leader in its frequency in both groups; more than half of the patients were found to have CHD and atherosclerosis; cerebrovascular disorders were less common.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>псориатический артрит</kwd><kwd>кардиоваскулярные заболевания</kwd></kwd-group><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>psoriatic arthritis</kwd><kwd>cardiovascular diseases</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Machado-Pinto JM, Diniz MS, Bavoso NC. Psoriasis: new comorbidities. Ann Bras Dermatol. 2016;91(1):8-16. doi: 10.1590/abd1806-4841.20164169</mixed-citation><mixed-citation xml:lang="en">Machado-Pinto JM, Diniz MS, Bavoso NC. Psoriasis: new comorbidities. Ann Bras Dermatol. 2016;91(1):8-16. doi: 10.1590/abd1806-4841.20164169</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Masson W, Rossi E, Galimberti ML, et al. Mortality in patients with psoriasis. A retrospective cohort study. Med Clin (Barc). 2017;148(11):483-8. doi: 10.1016/j.medcli.2016.12.011</mixed-citation><mixed-citation xml:lang="en">Masson W, Rossi E, Galimberti ML, et al. Mortality in patients with psoriasis. A retrospective cohort study. Med Clin (Barc). 2017;148(11):483-8. doi: 10.1016/j.medcli.2016.12.011</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Маркелова ЕИ, Коротаева ТВ, Новикова ДС и др. Распространенность метаболического синдрома у больных псориатическим аритритом: его связь с воспалением и субклиническим атеросклерозом. Научно-практическая ревматология. 2016;54(Прил 1):20-4 [Markelova EI, Korotaeva TV, Novikova DS, et al. Prevalence of metabolic syndrome in patients with psoriatic arthritis: Its association with inflammation and subclinical atherosclerosis. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54 Suppl. 1:20-4 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-20-24</mixed-citation><mixed-citation xml:lang="en">Маркелова ЕИ, Коротаева ТВ, Новикова ДС и др. Распространенность метаболического синдрома у больных псориатическим аритритом: его связь с воспалением и субклиническим атеросклерозом. Научно-практическая ревматология. 2016;54(Прил 1):20-4 [Markelova EI, Korotaeva TV, Novikova DS, et al. Prevalence of metabolic syndrome in patients with psoriatic arthritis: Its association with inflammation and subclinical atherosclerosis. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54 Suppl. 1:20-4 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-20-24</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Eder L, Zisman D, Barzilai M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case control study. J Rheumatol. 2008;35:877-82.</mixed-citation><mixed-citation xml:lang="en">Eder L, Zisman D, Barzilai M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case control study. J Rheumatol. 2008;35:877-82.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Augustin M, Vietri J, Tian H, et al. Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J Eur Acad Dermatol Venereol. 2017 Apr 20. doi: 10.1111/jdv.14286</mixed-citation><mixed-citation xml:lang="en">Augustin M, Vietri J, Tian H, et al. Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J Eur Acad Dermatol Venereol. 2017 Apr 20. doi: 10.1111/jdv.14286</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bengtsson K, Forsblad-d'Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017 May 18;19(1):102. doi: 10.1186/s13075-017-1315-z</mixed-citation><mixed-citation xml:lang="en">Bengtsson K, Forsblad-d'Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017 May 18;19(1):102. doi: 10.1186/s13075-017-1315-z</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ding HS, Yang J, Jang J, et al. Interleukin-17 contributes to cardiovascular diseases. Mol Biol Rep. 2012;39(7):7473-8. doi: 10.1007/s11033-012-1580-5</mixed-citation><mixed-citation xml:lang="en">Ding HS, Yang J, Jang J, et al. Interleukin-17 contributes to cardiovascular diseases. Mol Biol Rep. 2012;39(7):7473-8. doi: 10.1007/s11033-012-1580-5</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96. doi: 10.1038/jid.2010.103</mixed-citation><mixed-citation xml:lang="en">Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96. doi: 10.1038/jid.2010.103</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mehta NN, Yu Yi, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG-PET/CT). Arch Dermatol. 2011;147(9);1031-9. doi: 10.1001/archdermatol. 2011.119</mixed-citation><mixed-citation xml:lang="en">Mehta NN, Yu Yi, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG-PET/CT). Arch Dermatol. 2011;147(9);1031-9. doi: 10.1001/archdermatol. 2011.119</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ogdie A, Haynes K, Troxel AB, et al. The risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2014,73(1):149-53. doi: 10.1136/annrheumdis-2012-202424</mixed-citation><mixed-citation xml:lang="en">Ogdie A, Haynes K, Troxel AB, et al. The risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2014,73(1):149-53. doi: 10.1136/annrheumdis-2012-202424</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Malbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatient. Eur J Epidemiol. 2004;19:225-30. doi: 10.1023/B:EJEP.0000020447.59150.f9</mixed-citation><mixed-citation xml:lang="en">Malbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatient. Eur J Epidemiol. 2004;19:225-30. doi: 10.1023/B:EJEP.0000020447.59150.f9</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Marshall V, Farah M, Hawkins S, et al. Cardiovascular Disease Outcomes Associated with Three Major Inflammatory Dermatologic Diseases: A propensity-matched case control study. Dermatol Ther (Heidelb). 2016;6:649-58. doi: 10.1007/S13555-016-0144-3</mixed-citation><mixed-citation xml:lang="en">Marshall V, Farah M, Hawkins S, et al. Cardiovascular Disease Outcomes Associated with Three Major Inflammatory Dermatologic Diseases: A propensity-matched case control study. Dermatol Ther (Heidelb). 2016;6:649-58. doi: 10.1007/S13555-016-0144-3</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Qureshi A, Choi HK, Curhan GC. Psoriasis and the risk of diabetes and hypertension – a prospective study of US female nurses. Arch Dermatol. 2009;145(4):379-82. doi: 10.1001/archdermatol.2009.48</mixed-citation><mixed-citation xml:lang="en">Qureshi A, Choi HK, Curhan GC. Psoriasis and the risk of diabetes and hypertension – a prospective study of US female nurses. Arch Dermatol. 2009;145(4):379-82. doi: 10.1001/archdermatol.2009.48</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Augustin M, Reich K, Glaeske G, et al. Co-morbidity and agerelated prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147-50. doi: 10.234/00015555-0770</mixed-citation><mixed-citation xml:lang="en">Augustin M, Reich K, Glaeske G, et al. Co-morbidity and agerelated prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147-50. doi: 10.234/00015555-0770</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Takeshita J, Wang S, Shin DB, et al. Effect of Psoriasis Severity on Hypertension Control: A population-based study in the United Kingdom. JAMA Dermatol. 2015;151(2):161-9. doi: 10.1001/jamadewrmatol.2014.2094</mixed-citation><mixed-citation xml:lang="en">Takeshita J, Wang S, Shin DB, et al. Effect of Psoriasis Severity on Hypertension Control: A population-based study in the United Kingdom. JAMA Dermatol. 2015;151(2):161-9. doi: 10.1001/jamadewrmatol.2014.2094</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen AD, Weitzman D, Dreiher J, et al. Psoriasis and hypertension: a case control study. Acta Derm-Venerol. 2010;90(1):23-6. doi: 10.2340/00015555-0741</mixed-citation><mixed-citation xml:lang="en">Cohen AD, Weitzman D, Dreiher J, et al. Psoriasis and hypertension: a case control study. Acta Derm-Venerol. 2010;90(1):23-6. doi: 10.2340/00015555-0741</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and metaanalysis of observational studies. J Hypertens. 2013;31(3):433-43. doi: 10.1097/HJH.0b013e32835bcce1</mixed-citation><mixed-citation xml:lang="en">Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and metaanalysis of observational studies. J Hypertens. 2013;31(3):433-43. doi: 10.1097/HJH.0b013e32835bcce1</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875- 83. doi: 10.1007/s00403-015-1593-8</mixed-citation><mixed-citation xml:lang="en">Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875- 83. doi: 10.1007/s00403-015-1593-8</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Karbach S, Croxford AL, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction and artherial hypertension in psoriasis-like skin disease. Atheroscler Thromb Vasc Biol. 2014;34(12):230-6. doi: 10.1161/ATVBBAHA.114.304108</mixed-citation><mixed-citation xml:lang="en">Karbach S, Croxford AL, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction and artherial hypertension in psoriasis-like skin disease. Atheroscler Thromb Vasc Biol. 2014;34(12):230-6. doi: 10.1161/ATVBBAHA.114.304108</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritits inpatients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-35. doi: 10.1016/jaad.2013.07.023</mixed-citation><mixed-citation xml:lang="en">Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritits inpatients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-35. doi: 10.1016/jaad.2013.07.023</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ и др. Поражение костно-суставного аппарата у больных псориазом по данным скринингового опросника PEST (Psoriasis Epydemiology Screening Tool) и ревматологического клинико-инструментального обследования. Научно-практическая ревматология. 2014;52(6):636-42 [Chamurlieva MN, Loginova EYu, Korotaeva TV, et al. Osteoarticular injury in psoriatic patients according to the data of PEST (Psoriasis Epidemiology Screening Tool) questionnaire and rheumatological clinicoinstrumental examination. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(6):636-42 (In Russ.)]. doi: 10.14412/1995- 4484-2014-636-642</mixed-citation><mixed-citation xml:lang="en">Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ и др. Поражение костно-суставного аппарата у больных псориазом по данным скринингового опросника PEST (Psoriasis Epydemiology Screening Tool) и ревматологического клинико-инструментального обследования. Научно-практическая ревматология. 2014;52(6):636-42 [Chamurlieva MN, Loginova EYu, Korotaeva TV, et al. Osteoarticular injury in psoriatic patients according to the data of PEST (Psoriasis Epidemiology Screening Tool) questionnaire and rheumatological clinicoinstrumental examination. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(6):636-42 (In Russ.)]. doi: 10.14412/1995- 4484-2014-636-642</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Choi JW, Kim BR, Youn SW. Could psoriatic arthritits be easily diagnosed from current suspicious physical findings in dermatology clinic? Ann Dermatol. 2017;29(1):48-54. doi: 10.5021/ad.2017.29.1.48</mixed-citation><mixed-citation xml:lang="en">Choi JW, Kim BR, Youn SW. Could psoriatic arthritits be easily diagnosed from current suspicious physical findings in dermatology clinic? Ann Dermatol. 2017;29(1):48-54. doi: 10.5021/ad.2017.29.1.48</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013 Jan;149(1):84-91. doi: 10.1001/2013.jamadermatol.406</mixed-citation><mixed-citation xml:lang="en">Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013 Jan;149(1):84-91. doi: 10.1001/2013.jamadermatol.406</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Dogan S, Atakan N. Psoriasis: A disease of systemic inflammation with comorbidities. In: Lima H, editor. Psoriasis – Types, Causes and Medication. InTech; 2013. Avalable from: http://www.intechopen.com/books/psoriasis-types-causes-andmedication/psoriasis-a-disease-of-systemic-inflammation-withcomorbidities</mixed-citation><mixed-citation xml:lang="en">Dogan S, Atakan N. Psoriasis: A disease of systemic inflammation with comorbidities. In: Lima H, editor. Psoriasis – Types, Causes and Medication. InTech; 2013. Avalable from: http://www.intechopen.com/books/psoriasis-types-causes-andmedication/psoriasis-a-disease-of-systemic-inflammation-withcomorbidities</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Frers KRA, Bisoendial RJ. Montoya SF, et al. Psoriasis and cardiovascular risk: Immune- mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metabol Endocr. 2015;6:43-54. doi: 10.1016/j.ijcme.2015.01.005</mixed-citation><mixed-citation xml:lang="en">Frers KRA, Bisoendial RJ. Montoya SF, et al. Psoriasis and cardiovascular risk: Immune- mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metabol Endocr. 2015;6:43-54. doi: 10.1016/j.ijcme.2015.01.005</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Sundarrajan S, Arumugam M. Comorbidities of psoriasis-exploring the links by network approach. PLoS ONE. 2016;11(3):e0149175. doi: 10.1371/journal.pone.0149175</mixed-citation><mixed-citation xml:lang="en">Sundarrajan S, Arumugam M. Comorbidities of psoriasis-exploring the links by network approach. PLoS ONE. 2016;11(3):e0149175. doi: 10.1371/journal.pone.0149175</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gulliver WP. Genetic targets for the future treatment of psoriasis including HLA-Cw6. Presented at: 21st World Congress of Dermatology, 30 September – 5 October 2007, Buenos Aires, Argentina.</mixed-citation><mixed-citation xml:lang="en">Gulliver WP. Genetic targets for the future treatment of psoriasis including HLA-Cw6. Presented at: 21st World Congress of Dermatology, 30 September – 5 October 2007, Buenos Aires, Argentina.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">O'Reilly DD, Rahman P. Genetic, epigenetic and pharmacogenetic aspects of psoriasis and psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):623-42. doi: 10.1016/j.rdc.2015.07.002</mixed-citation><mixed-citation xml:lang="en">O'Reilly DD, Rahman P. Genetic, epigenetic and pharmacogenetic aspects of psoriasis and psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):623-42. doi: 10.1016/j.rdc.2015.07.002</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273:197-204. doi: 10.1111/j.1365-2796.2012.02593.x</mixed-citation><mixed-citation xml:lang="en">Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273:197-204. doi: 10.1111/j.1365-2796.2012.02593.x</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Roubille C, Richer V, Starnino T, et al. The effects of tumor necrosis factor inhibitors, methotrexate, non-steroidal antiinflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-9. doi: 10.1136/annrheumdis-2014-206624</mixed-citation><mixed-citation xml:lang="en">Roubille C, Richer V, Starnino T, et al. The effects of tumor necrosis factor inhibitors, methotrexate, non-steroidal antiinflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-9. doi: 10.1136/annrheumdis-2014-206624</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22:341-4. doi: 10.1111/j.1468-3083.2007.02429.x</mixed-citation><mixed-citation xml:lang="en">Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22:341-4. doi: 10.1111/j.1468-3083.2007.02429.x</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007;87:506-9. doi: 10.2340/00015555-0297</mixed-citation><mixed-citation xml:lang="en">Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007;87:506-9. doi: 10.2340/00015555-0297</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-9. doi: 10.1001/archderm.143.12.1493</mixed-citation><mixed-citation xml:lang="en">Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-9. doi: 10.1001/archderm.143.12.1493</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
